v3.25.4
Nature of Business and Significant Accounting Policies (Details Narrative) - USD ($)
 12 Months Ended
Apr. 20, 2023
Sep. 30, 2025
Sep. 30, 2024
Schedule of Equity Method Investments [Line Items]      
Allowance for credit losses   $ 620,000 $ 620,000
Advertising expense   $ 37,993 $ 22,205
Antidilutive securities earning per share   112,058,166 104,490,131
Conversion of preferred shares   8,340,000  
Series A Convertible Preferred Stock [Member]      
Schedule of Equity Method Investments [Line Items]      
Conversion of preferred shares   13,579,710 13,579,710
Series B Convertible Preferred Stock [Member]      
Schedule of Equity Method Investments [Line Items]      
Conversion of preferred shares   13,579,710 13,579,710
Series D Convertible Preferred Stock [Member]      
Schedule of Equity Method Investments [Line Items]      
Conversion of preferred shares   390,250 0
Share-Based Payment Arrangement, Option [Member]      
Schedule of Equity Method Investments [Line Items]      
Antidilutive securities earning per share   9,920,000 8,120,000
Warrant [Member]      
Schedule of Equity Method Investments [Line Items]      
Antidilutive securities earning per share   17,387,050 15,387,050
Discontinued Operations, Held-for-Sale [Member] | Purchase Agreement [Member]      
Schedule of Equity Method Investments [Line Items]      
Cash purchase price $ 2,300,000